# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-22-104271
Filing Date
2022-04-13
Accepted
2022-04-13 16:07:55
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | d327559ddefa14a.htm | DEFA14A | 11253
2 | GRAPHIC | g327559g32d86.jpg | GRAPHIC | 463911
3 | GRAPHIC | g327559g33e15.jpg | GRAPHIC | 295897
| Complete submission text file | 0001193125-22-104271.txt |  | 1058961

Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39782 | Film No.: 22824791
SIC: 2836 Biological Products, (No Diagnostic Substances)